HC Wainwright Has Positive Outlook of CRDL FY2028 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Stock analysts at HC Wainwright boosted their FY2028 earnings per share (EPS) estimates for Cardiol Therapeutics in a research note issued to investors on Friday, August 15th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of $0.51 for the year, up from their prior estimate of $0.40. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2029 earnings at $1.05 EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04.

Cardiol Therapeutics Price Performance

Cardiol Therapeutics stock opened at $1.14 on Monday. The firm has a market capitalization of $95.43 million, a P/E ratio of -3.35 and a beta of 1.05. Cardiol Therapeutics has a one year low of $0.7709 and a one year high of $2.63. The business has a fifty day moving average price of $1.33 and a 200-day moving average price of $1.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.46 and a quick ratio of 3.26.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRDL. Tejara Capital Ltd grew its holdings in shares of Cardiol Therapeutics by 2.2% during the 2nd quarter. Tejara Capital Ltd now owns 3,265,819 shares of the company’s stock worth $4,442,000 after acquiring an additional 70,829 shares during the period. PVG Asset Management Corp bought a new position in Cardiol Therapeutics in the 4th quarter worth $624,000. Lion Street Advisors LLC increased its stake in Cardiol Therapeutics by 8.5% in the 1st quarter. Lion Street Advisors LLC now owns 333,725 shares of the company’s stock worth $318,000 after buying an additional 26,059 shares in the last quarter. Envestnet Asset Management Inc. purchased a new position in shares of Cardiol Therapeutics during the fourth quarter valued at about $398,000. Finally, Cetera Investment Advisers purchased a new position in Cardiol Therapeutics in the fourth quarter worth about $56,000. Hedge funds and other institutional investors own 12.49% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.